Literature DB >> 18665786

Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States.

Sarah J Glover1, Martin Gall, Oliver Schoenborn-Kellenberger, Michael Wagener, Patrick Garnero, Steven Boonen, Jane A Cauley, Dennis M Black, Pierre D Delmas, Richard Eastell.   

Abstract

Robust reference intervals are needed for the interpretation of bone turnover markers in large phase III fracture trials. The objectives of the study were to (1) estimate reference intervals for serum bone alkaline phosphatase (bone ALP), serum procollagen type I N propeptide (PINP), serum beta cross-linked C-telopeptides of type I collagen (S-betaCTX), and urinary cross-linked N-telopeptides of type I collagen (U-NTX) in healthy young premenopausal women; (2) examine geographical differences on bone turnover markers; and (3) assess factors known to influence bone turnover and test whether these explain any regional differences. We studied 637 eligible women from four countries that participated in the Horizon-PFT study (United Kingdom, France, Belgium, United States). The women were 30-39 yr of age (mean, 34.6 yr), with regular cyclic menses. Subjects completed a medical and lifestyle questionnaire. Two-sided 95% reference intervals were estimated on transformed values and transformed back to the original scale using the proposed methodology of the International Federation of Clinical Chemistry. S-betaCTX was significantly higher in France relative to the United Kingdom (p = 0.01), and PINP was higher in France (p < 0.001) and Belgium (p = 0.02) relative to the United Kingdom and significantly higher in France relative to the United States (p < 0.01) by ANOVA. Overall, one could associate low bone turnover markers with nonsmoking, use of a contraceptive pill, exercise, being close to the time of ovulation, and having high 25-hydroxyvitamin D levels. Countries differed by these characteristics, and once allowed for in the statistical model, any country differences were attenuated or removed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18665786     DOI: 10.1359/jbmr.080703

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  43 in total

Review 1.  Bone turnover markers: use in osteoporosis.

Authors:  Kim Naylor; Richard Eastell
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

2.  Soluble Tumor Necrosis Factor Alpha Receptor 1, Bone Resorption, and Bone Mineral Density in the Year Following Hip Fractures: The Baltimore Hip Studies.

Authors:  Shabnam Salimi; Michelle Shardell; Ram Miller; Ann L Gruber-Baldini; Denise Orwig; Neal Fedarko; Marc C Hochberg; Jack M Guralnik; Jay Magaziner
Journal:  J Bone Miner Res       Date:  2018-06-15       Impact factor: 6.741

3.  Seasonal variation of bone turnover markers in top-level female skiers.

Authors:  Giovanni Lombardi; Alessandra Colombini; Marco Freschi; Rodolfo Tavana; Giuseppe Banfi
Journal:  Eur J Appl Physiol       Date:  2010-09-29       Impact factor: 3.078

4.  Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China.

Authors:  X-Y Wu; H Zhang; H Xie; X-H Luo; Y-Q Peng; L-Q Yuan; R-C Dai; Z-F Sheng; X-P Wu; E-Y Liao
Journal:  Osteoporos Int       Date:  2013-07-23       Impact factor: 4.507

5.  The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women.

Authors:  Elma Kučukalić-Selimović; Amina Valjevac; Almira Hadžović-Džuvo
Journal:  Bosn J Basic Med Sci       Date:  2013-11       Impact factor: 3.363

Review 6.  Bone markers in osteoporosis.

Authors:  Patrick Garnero
Journal:  Curr Osteoporos Rep       Date:  2009-09       Impact factor: 5.096

Review 7.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

Review 8.  Site specific measurements of bone formation using [18F] sodium fluoride PET/CT.

Authors:  Glen M Blake; Tanuj Puri; Musib Siddique; Michelle L Frost; Amelia E B Moore; Ignac Fogelman
Journal:  Quant Imaging Med Surg       Date:  2018-02

9.  Distribution of serum βCTX in a population-based study of postmenopausal women taking into account different anti-osteoporotic therapies (the FRODOS Cohort).

Authors:  Eduardo Kanterewicz; Pilar Peris; Emma Puigoriol; Aina Yáñez; Pau Rosique; Luis Del Rio
Journal:  J Bone Miner Metab       Date:  2012-12-08       Impact factor: 2.626

10.  Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).

Authors:  A L Schafer; A J Burghardt; D E Sellmeyer; L Palermo; D M Shoback; S Majumdar; D M Black
Journal:  Osteoporos Int       Date:  2013-04-16       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.